Unknown

Dataset Information

0

Protein kinase C (PKC) participates in acetaminophen hepatotoxicity through c-jun-N-terminal kinase (JNK)-dependent and -independent signaling pathways.


ABSTRACT: This study examines the role of protein kinase C (PKC) and AMP-activated kinase (AMPK) in acetaminophen (APAP) hepatotoxicity. Treatment of primary mouse hepatocytes with broad-spectrum PKC inhibitors (Ro-31-8245, Go6983), protected against APAP cytotoxicity despite sustained c-jun-N-terminal kinase (JNK) activation. Broad-spectrum PKC inhibitor treatment enhanced p-AMPK levels and AMPK regulated survival-energy pathways including autophagy. AMPK inhibition by compound C or activation using an AMPK activator oppositely modulated APAP cytotoxicity, suggesting that p-AMPK and AMPK regulated energy survival pathways, particularly autophagy, play a critical role in APAP cytotoxicity. Ro-31-8245 treatment in mice up-regulated p-AMPK levels, increased autophagy (i.e., increased LC3-II formation, p62 degradation), and protected against APAP-induced liver injury, even in the presence of sustained JNK activation and translocation to mitochondria. In contrast, treatment of hepatocytes with a classical PKC inhibitor (Go6976) protected against APAP by inhibiting JNK activation. Knockdown of PKC-? using antisense (ASO) in mice also protected against APAP-induced liver injury by inhibiting JNK activation. APAP treatment resulted in PKC-? translocation to mitochondria and phosphorylation of mitochondrial PKC substrates. JNK 1 and 2 silencing in vivo decreased APAP-induced PKC-? translocation to mitochondria, suggesting PKC-? and JNK interplay in a feed-forward mechanism to mediate APAP-induced liver injury.PKC-? and other PKC(s) regulate death (JNK) and survival (AMPK) proteins, to modulate APAP-induced liver injury.

SUBMITTER: Saberi B 

PROVIDER: S-EPMC3997165 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein kinase C (PKC) participates in acetaminophen hepatotoxicity through c-jun-N-terminal kinase (JNK)-dependent and -independent signaling pathways.

Saberi Behnam B   Ybanez Maria D MD   Johnson Heather S HS   Gaarde William A WA   Han Derick D   Kaplowitz Neil N  

Hepatology (Baltimore, Md.) 20140303 4


<h4>Unlabelled</h4>This study examines the role of protein kinase C (PKC) and AMP-activated kinase (AMPK) in acetaminophen (APAP) hepatotoxicity. Treatment of primary mouse hepatocytes with broad-spectrum PKC inhibitors (Ro-31-8245, Go6983), protected against APAP cytotoxicity despite sustained c-jun-N-terminal kinase (JNK) activation. Broad-spectrum PKC inhibitor treatment enhanced p-AMPK levels and AMPK regulated survival-energy pathways including autophagy. AMPK inhibition by compound C or ac  ...[more]

Similar Datasets

| S-EPMC6592188 | biostudies-literature
| S-EPMC4549164 | biostudies-literature
| S-EPMC3353249 | biostudies-literature
| S-EPMC85571 | biostudies-literature
| S-EPMC8550922 | biostudies-literature
| S-EPMC3186406 | biostudies-literature
| S-EPMC7452742 | biostudies-literature
| S-EPMC4394340 | biostudies-literature
| S-EPMC3343059 | biostudies-literature
| S-EPMC8896658 | biostudies-literature